MindWalk Holdings (HYFT) Total Current Liabilities (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Total Current Liabilities of $4.2 million for Q2 2026, down 33.32% year-over-year from $6.3 million in Q2 2025, and up 16.52% quarter-over-quarter from $3.6 million in Q1 2026.
MindWalk Holdings (HYFT) Total Current Liabilities (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Total Current Liabilities for 7 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities fell 33.32% year-over-year to $4.2 million; the TTM figure through Apr 2026 stood at $4.2 million (down 33.32% YoY), while the FY2026 annual figure was $4.2 million, down 34.72% from the prior year.
- Total Current Liabilities grew to $4.2 million in Q2 2026 per HYFT's latest filing, from $3.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $12.1 million in Q3 2025 and bottomed at $3.6 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $6.0 million across 5 years, with a median of $5.6 million in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 69.65% — and 2025, when it plunged 58.82%.
- MindWalk Holdings' Total Current Liabilities stood at $5.5 million in 2022, then grew by 1.01% to $5.6 million in 2023, then jumped by 63.54% to $9.1 million in 2024, then slumped by 58.82% to $3.7 million in 2025, then rose by 12.85% to $4.2 million in 2026.
- Business Quant data shows HYFT's Total Current Liabilities at $4.2 million in Q2 2026, $3.6 million in Q1 2026, and $3.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.22 Mn |
| Jan 31, 2026 | 3.62 Mn |
| Oct 31, 2025 | 3.74 Mn |
| Jul 31, 2025 | 12.15 Mn |
| Apr 30, 2025 | 6.33 Mn |
| Jan 31, 2025 | 6.29 Mn |
| Oct 31, 2024 | 9.09 Mn |
| Jul 31, 2024 | 8.16 Mn |
| Apr 30, 2024 | 5.99 Mn |
| Jan 31, 2024 | 6.72 Mn |
| Oct 31, 2023 | 5.56 Mn |
| Jul 31, 2023 | 4.81 Mn |
| Apr 30, 2023 | 4.38 Mn |
| Jan 31, 2023 | 4.93 Mn |
| Oct 31, 2022 | 5.50 Mn |
| Jul 31, 2022 | 4.16 Mn |
| Apr 30, 2022 | 7.34 Mn |
| Jan 31, 2022 | 5.64 Mn |
| Oct 31, 2021 | 5.99 Mn |
| Jul 31, 2021 | 5.39 Mn |